Landed Cost Calculator
Calculate Landed Cost for Pharmaceuticals from India
India pharmaceutical imports present a dual-layer compliance challenge in 2026: 0% base MFN rate for most finished dosage forms, but 15% Section 122 surcharge active through July 24, plus FDA regulatory requirements that can stop shipments regardless of duty status. India is the largest generic drug supplier to the US — FDA maintains active Import Alerts targeting facilities with GMP violations. This calculator is pre-loaded with India pharma defaults — enter your shipment value to get the full cost breakdown.
<\!-- Current Rate Snapshot -->Base MFN (Finished Drugs)
0%
HTS 3004 most finished formulations
Base MFN (APIs/Chemicals)
0%–6.5%
HTS Ch. 29 active pharmaceutical ingredients
Section 122 Surcharge
15%
Active Feb 24 – Jul 24, 2026 (all countries)
FDA PDUFA User Fee
Varies
Annual facility + product fees apply
India Pharmaceuticals Duty Rates — HTS Quick Reference (2026)
| Product | HTS Code | Base MFN | Section 301 | Notes |
|---|---|---|---|---|
| Finished dosage forms (mixed) | 3004.90 | 0% | None | FDA 510(k)/ANDA required |
| Antibiotics, packaged | 3004.10 | 0% | None | FDA facility registration req. |
| Vitamins, packaged | 3004.50 | 0% | None | Dietary supplement rules apply |
| Active pharmaceutical ingredients (APIs) | 2941.90 | 0%–3.7% | None | EP/USP spec. docs required |
| Organic chemicals (intermediates) | 2933.99 | 3.7%–6.5% | Check | TSCA review may apply |
| Vaccines | 3002.20 | 0% | None | FDA biologics license req. |
| Diagnostic reagents | 3822.19 | 0% | None | FDA 510(k) clearance |
India pharmaceuticals are NOT subject to Section 301. Section 122 (15%) applies through July 24, 2026. FDA regulatory compliance costs are separate from and in addition to customs duties. Consult FDA import resources before importing.
Key Regulatory Context for India Pharmaceutical Importers (2026)
- FDA Oversight is the Primary Risk: Pharmaceutical imports from India face intense FDA scrutiny. India is the largest supplier of generic drugs to the US market, and FDA maintains active Import Alerts (especially Import Alert 66-40) that can result in detention without physical examination (DWPE) for facilities with GMP violations. Confirm your Indian manufacturer's FDA registration status before importing.
- Drug Import Alert 66-40: FDA's Import Alert 66-40 covers unapproved new drugs. India-manufactured drugs that lack FDA approval (ANDA, NDA, or OTC monograph coverage) are subject to automatic detention. This is not a tariff issue — it's a regulatory admission that stops shipments before CBP processes the entry.
- HTS Chapter 29 vs. 30 Classification: Finished dosage forms (tablets, capsules, liquids) are Chapter 30. Active pharmaceutical ingredients (APIs) are typically Chapter 29 (organic chemicals). This distinction affects duty rates and reporting requirements. Misclassification between API and finished dosage form is a common CBP audit trigger.
- Section 122 (15% Global Surcharge): India pharmaceutical imports are subject to Section 122 (15%, active Feb 24 – Jul 24, 2026). For zero-duty finished drugs (HTS 3004), Section 122 represents the entire duty burden during the active period — effectively a 15% tariff on CIF value.
- USFDA Facility Registration: All facilities that manufacture, repack, relabel, or hold pharmaceutical products for import into the US must register with FDA under 21 CFR Part 207. Failure to register results in import refusal. Registration must be renewed biennially in odd-numbered years.
Frequently Asked Questions — India Pharmaceuticals Landed Cost
What is the import duty rate for finished pharmaceutical drugs from India?
Most finished pharmaceutical dosage forms (HTS 3004) enter the US at a 0% base MFN tariff rate. India is not subject to Section 301 tariffs on pharmaceuticals. However, Section 122 (15% global surcharge, active Feb 24 – Jul 24, 2026) applies to all countries including India — so the effective duty during this period is 15% on CIF customs value. MPF (0.3464%, minimum $32.71) also applies. The effective total cost-add for most India pharma imports in 2026 is approximately 15.3% of customs value during the Section 122 active period.
Are active pharmaceutical ingredients (APIs) from India subject to tariffs?
APIs from India (HTS Chapter 29) face base MFN rates ranging from 0% to 6.5% depending on the specific chemical. Section 301 does not apply to India. Section 122 (15%) applies through July 2026. The total duty burden for APIs depends on the specific HTS 8/10-digit code — organic chemistry intermediates (HTS 2933, 2934) often face higher base rates than antibiotics or vitamins. Use the USTradeStack HTS Classifier to confirm the exact rate for your API.
What is FDA Import Alert 66-40 and how does it affect India pharma imports?
FDA Import Alert 66-40 covers unapproved new drugs and lists firms whose products are subject to detention without physical examination (DWPE). If your Indian manufacturer is on this list, FDA will refuse admission of their products regardless of CBP/duty status. You can check the status of any Indian pharmaceutical manufacturer on FDA's Import Alert database at accessdata.fda.gov. Removal from an Import Alert requires demonstrating corrective actions and GMP compliance to FDA's satisfaction.
What documents are required to import pharmaceuticals from India?
Required documents for pharma imports from India: (1) Commercial invoice with HTS code, country of origin, and customs value; (2) FDA registration number for the manufacturing facility; (3) Drug Establishment Registration and Drug Listing for the manufacturer; (4) Certificate of Analysis (CoA) meeting EP/USP/BP specifications; (5) FDA Drug Application number (NDA/ANDA) or OTC monograph basis; (6) Freight/import documentation (AWB or B/L, packing list). FDA may also request batch records, stability data, or GMP inspection reports for detained shipments.
How does Section 122 affect pharmaceutical import costs from India?
Section 122 (15% global tariff surcharge, effective Feb 24 – Jul 24, 2026) applies to pharmaceutical imports from India. For finished drugs with a 0% base MFN rate, Section 122 represents the entire duty liability — effectively adding 15% to customs value. For a $1,000,000 shipment of finished dosage forms, Section 122 adds $150,000 in duties. APIs with existing base MFN rates of 3–6% face Section 122 stacked on top. This calculator includes Section 122 in all calculations.
Are Indian generic drugs subject to antidumping duties?
No. There are no active antidumping or countervailing duty (AD/CVD) orders on pharmaceutical products from India as of 2026. AD/CVD is more common in commodity chemicals, steel, and electronics. India pharmaceutical imports face standard MFN duty rates plus Section 122. The main non-tariff barrier for India pharma is FDA regulatory compliance — GMP issues, Import Alerts, and facility registration problems are far more likely to stop a pharma shipment than duty rates.
Get Weekly India Trade & Pharma Import Updates
FDA Import Alert changes, Section 122 updates, and API duty rate changes — weekly intel for pharmaceutical importers.
Related Tools & Guides
Educational estimates only — actual duties determined by CBP at time of entry. FDA regulatory requirements are separate from and in addition to CBP import duties. Consult a licensed customs broker or trade attorney before making sourcing decisions. Tariff rates effective as of April 2026. AI Disclaimer · Terms